How to Get Avodart (Dutasteride) in Missouri

What Is Dutasteride and Why Do Missouri Patients Seek It?

Dutasteride is a dual 5-alpha-reductase inhibitor that blocks both type 1 and type 2 isoenzymes, reducing serum dihydrotestosterone (DHT) by roughly 90 to 95 percent within two weeks of daily dosing. Finasteride, the other common 5-ARI, suppresses DHT by only about 70 percent by blocking type 2 alone. The FDA approved dutasteride under the brand name Avodart in November 2001 for symptomatic BPH in men with an enlarged prostate. The approval label specifies 0.5 mg orally once daily as the sole approved dose.

Off-label prescribing for androgenetic alopecia has grown substantially. A randomized controlled trial by Eun et al. (J Am Acad Dermatol, 2010, N=153) compared dutasteride 0.5 mg daily to finasteride 1 mg daily and placebo over 24 weeks. Dutasteride produced statistically greater increases in total hair count and hair weight than finasteride at the 12-week and 24-week time points (P<0.05 at both assessments). That single trial is frequently cited in clinical decision-making, though it was conducted in Korean men and may not generalize to all populations.

Missouri's population of roughly 6.2 million includes approximately 430,000 men over age 50, a demographic with meaningful BPH prevalence. The American Urological Association estimates BPH affects over 50 percent of men in their 60s and up to 90 percent by their 80s. Demand for telehealth access to dutasteride has increased since Missouri formalized synchronous audio-visual prescribing rules in 2020.

Missouri Telehealth Rules for Dutasteride Prescriptions

Missouri permits telehealth prescribing of dutasteride. State law does not require an in-person visit before a Schedule-exempt non-controlled substance like dutasteride is prescribed via telemedicine. Missouri Revised Statutes Section 191.1145 governs telehealth practice and requires that a valid patient-provider relationship be established before any prescription is issued. The Missouri State Board of Registration for the Healing Arts defines that relationship as including a documented medical history, an appropriate clinical evaluation, and a diagnosis consistent with the prescription.

Telehealth platforms operating in Missouri must hold a Missouri provider license or employ Missouri-licensed prescribers. Asynchronous-only (store-and-forward) prescribing without a synchronous visit is a gray area under current Missouri rules; most compliance-focused telehealth services use live video or phone calls to stay clearly within the statute. The Federation of State Medical Boards' telemedicine policy guidance recommends synchronous evaluation as the standard for new prescriptions, and Missouri-licensed platforms generally follow that recommendation.

Patients should confirm before scheduling that the telehealth provider's prescriber holds an active Missouri medical license. The Missouri Division of Professional Registration maintains a searchable license lookup at pr.mo.gov. A consultation for dutasteride via telehealth typically runs 15 to 25 minutes and includes a symptom review, medication history, and PSA discussion for BPH cases.

Labs and Workup Required Before Starting Dutasteride in Missouri

A baseline prostate-specific antigen (PSA) measurement is the most consistently requested lab. The AUA Guideline on the Management of Benign Prostatic Hyperplasia (2023 update) states that PSA should be measured before initiating 5-ARI therapy because dutasteride suppresses PSA by approximately 50 percent after six months, which can obscure prostate cancer screening. Any PSA value obtained after dutasteride has been started should be doubled to approximate the pre-treatment equivalent.

Beyond PSA, the following are commonly ordered depending on indication:

• Serum creatinine and estimated GFR. Dutasteride is hepatically metabolized and renally excreted in small amounts, but renal impairment data are limited. The FDA prescribing information notes no formal studies in patients with renal impairment; clinicians typically order a basic metabolic panel at baseline.
• Liver function tests. Dutasteride undergoes extensive CYP3A4 hepatic metabolism. A pharmacokinetic review published on PubMed (Gisleskog et al., 2002) describes the hepatic elimination pathway in detail; baseline LFTs are prudent if the patient takes other CYP3A4-metabolized drugs.
• Total testosterone and DHT (optional). Some prescribers ordering dutasteride for hair loss request a baseline hormone panel to document pre-treatment DHT and to counsel patients on expected hormonal changes. Research indexed in PubMed on 5-ARI pharmacodynamics confirms that serum DHT falls by 90 to 95 percent within two weeks of starting 0.5 mg daily.
• Digital rectal exam. Not a lab, but the AUA guideline recommends DRE before initiating therapy in men with BPH symptoms to assess prostate size and detect nodules. Telehealth providers prescribing for BPH typically require patients to schedule a DRE with a local provider within 90 days of the first prescription.

For hair-loss-only visits at telehealth platforms, many providers accept self-reported history and a mailed PSA kit rather than requiring an in-person lab draw, provided the patient is under age 50 and has no prostate symptoms. Patients over 50 should have PSA drawn at a local LabCorp, Quest, or hospital outpatient lab before or concurrent with the telehealth visit.

Who Can Prescribe Dutasteride in Missouri?

Four categories of clinicians may legally prescribe dutasteride in Missouri.

Physicians (MD and DO). Any licensed Missouri physician with prescriptive authority may prescribe dutasteride independently, whether for the FDA-approved BPH indication or off-label for hair loss. Urologists, dermatologists, family medicine physicians, and internists all prescribe it routinely.

Nurse practitioners (NP). Missouri NPs with a full practice authority designation (granted after 2021 for NPs meeting experience thresholds under HB 1246) may prescribe independently. NPs still in a collaborative practice arrangement must have physician oversight on file, but dutasteride falls outside any controlled-substance restriction. The Missouri State Board of Nursing maintains licensure records for NPs.

Physician assistants (PA). Missouri PAs prescribe under a written supervision agreement with a licensed physician. Dutasteride is non-scheduled, so no additional DEA-related restrictions apply. The supervising physician does not need to co-sign each individual prescription under current Missouri rules, though platforms vary in their internal policies.

Pharmacist prescribing. Missouri does not currently authorize independent pharmacist prescribing for dutasteride under any statewide collaborative drug therapy management protocol. A pharmacist may adjust doses under a specific CDTM agreement but cannot initiate therapy independently.

Pharmacy Options: Retail, Mail-Order, and 503A Compounding in Missouri

The table below organizes the three dispensing channels available to Missouri patients and the key trade-offs for each.

Retail and chain pharmacies. Generic dutasteride 0.5 mg capsules are stocked at the major chains operating in Missouri, including CVS, Walgreens, Walmart Pharmacy, Hy-Vee Pharmacy, and independent community pharmacies. GoodRx and similar discount programs typically price a 30-capsule supply of generic dutasteride between $18 and $45 cash pay, depending on the dispensing pharmacy and current negotiations. The FDA Orange Book lists multiple ANDA-approved generic manufacturers for dutasteride 0.5 mg capsules.

Mail-order pharmacies. BCBS of Missouri, Centene-managed MO HealthNet commercial plans, and most PBMs route maintenance medications like dutasteride to 90-day mail-order fills. Patients with commercial insurance covering BPH medications may pay a single co-pay for a 90-day supply rather than three separate monthly co-pays.

503A compounding pharmacies. Missouri-licensed 503A pharmacies may compound dutasteride into alternative formulations, most commonly topical solutions or lower-dose oral capsules (0.1 mg or 0.25 mg), when a prescriber documents a clinical rationale for the compounded formulation. The FDA's guidance on 503A pharmacies specifies that compounded drugs must be prepared pursuant to a valid prescription for an identified individual patient. Missouri-licensed 503A pharmacies are listed with the Missouri State Board of Pharmacy. Topical dutasteride 0.1% solution has been studied in small trials; a 2019 study published on PubMed (Moftah et al., N=90) found topical dutasteride produced statistically significant hair density increases versus vehicle (P<0.001) over 24 weeks, though systemic absorption data were not fully characterized in that study.

Patients should verify that any 503A pharmacy shipping to a Missouri address holds a current Missouri non-resident pharmacy permit if the pharmacy is located out of state. The Board of Pharmacy permit lookup is publicly accessible.

Insurance Coverage and Prior Authorization in Missouri

Missouri Medicaid (MO HealthNet) does not cover dutasteride for BPH or for hair loss in the standard fee-for-service formulary. The MO HealthNet Preferred Drug List (PDL) classifies 5-ARIs as non-covered for these indications, with coverage limited to specific diabetes-related protocols under some managed-care organization contracts. Patients on MO HealthNet should expect to pay out of pocket.

Commercial insurance coverage varies widely. Most major Missouri commercial plans (Anthem Blue Cross Blue Shield MO, Cigna, Aetna, United Healthcare) cover generic dutasteride for BPH under the generic Tier 1 or Tier 2 benefit when prescribed for the FDA-approved indication. Hair-loss prescriptions frequently trigger a prior authorization (PA) process because the indication is off-label.

Prior authorization documentation typically required in Missouri:

1. Diagnosis code (L64.0 or L64.8 for androgenetic alopecia; N40.1 for BPH with LUTS).
2. Documentation of trial and failure or contraindication to a preferred agent. For BPH, some plans require a prior trial of an alpha-1-blocker (tamsulosin, silodosin, or alfuzosin) before approving a 5-ARI.
3. PSA value dated within six months.
4. A letter of medical necessity from the prescriber explaining clinical rationale.

The American Hair Loss Association's prescribing guidance and published AUA BPH guidelines are both citable references that prescribers may attach to prior authorization appeals. An initial PA denial does not close the case. Missouri law (RSMo 376.1350) grants patients the right to an expedited external appeal within 72 hours when a service is denied as not medically necessary.

How Long Until You Receive Dutasteride in Missouri?

Timeline from first contact to first dose varies by pathway.

Telehealth to retail pharmacy. A same-day telehealth visit followed by an e-prescription sent to a local pharmacy typically results in medication availability within two to four hours of the visit, assuming the prescription does not require prior authorization.

Telehealth to mail-order. Mail-order processing adds two to five business days for standard shipping. Most platforms offer overnight or two-day shipping for an additional fee.

In-person specialist visit. Urology and dermatology wait times in Missouri range widely. Missouri's physician workforce data reported by the Missouri Department of Health and Senior Services show rural counties in the Ozarks and Bootheel regions have fewer than 10 urologists per 100,000 population. Telehealth effectively removes geographic barriers for those patients.

503A compounded formulations. Allow five to ten business days for compounding, quality testing, and shipping to the Missouri address.

Generic dutasteride 0.5 mg capsules from retail pharmacies are almost universally stocked. A pharmacist-level drug availability check at any major Missouri chain pharmacy typically confirms same-day or next-day stock.

Transferring an Existing Dutasteride Prescription to Missouri

A patient moving to Missouri or establishing care with a new Missouri provider can transfer a non-controlled prescription like dutasteride between pharmacies under standard pharmacy law. Missouri pharmacy regulations under 20 CSR 2220-6.050 permit pharmacies to accept transferred prescriptions for non-scheduled drugs, including the remaining refills.

The receiving Missouri pharmacy contacts the dispensing pharmacy directly to record the transfer. Electronic transfer via the National Council for Prescription Drug Programs (NCPDP) network is the most common method used between chains. A patient need not obtain a new prescription from a Missouri provider simply to transfer an existing valid prescription, as long as the original prescriber's license is current.

If the prescriber who wrote the original prescription is not licensed in Missouri and the patient wants continued refills without returning to an out-of-state provider, establishing care with a Missouri telehealth prescriber to obtain a new prescription is the cleanest solution. Most telehealth platforms serving Missouri complete this process in one synchronous video visit, with the new e-prescription transmitted to the pharmacy of the patient's choice the same day.

Side Effects Missouri Patients Ask About Most

Dutasteride's most reported adverse effects are sexual in nature. The REDUCE trial (N=8,231, published in NEJM 2010) found that dutasteride 0.5 mg daily over four years reduced the risk of prostate cancer detection by 22.8 percent relative to placebo, but the dutasteride group showed higher rates of erectile dysfunction (6.7 percent vs. 5.0 percent), decreased libido (3.3 percent vs. 1.6 percent), and ejaculation disorders (1.4 percent vs. 0.5 percent) compared with the placebo group. The FDA prescribing information carries a Class Warning about a potential increase in high-grade prostate cancer (Gleason score 8 to 10) based on pooled 5-ARI data, though the absolute risk increase was small and the clinical significance is debated.

Gynecomastia occurs in roughly 2.2 percent of patients over four years of use per the REDUCE data. Post-finasteride syndrome has been discussed in the literature in the context of persistent sexual adverse effects; a systematic review indexed at PubMed (Traish et al., 2015) reviewed the evidence base for persistent adverse effects with 5-ARIs, noting that the mechanistic evidence remains incomplete. Patients should discuss personal risk tolerance with their prescriber before starting therapy.

Dutasteride for Female Hair Loss in Missouri: What the Evidence Shows

Although the FDA approved dutasteride only in men for BPH, off-label use in women with androgenetic alopecia exists in clinical practice. A Cochrane-indexed systematic review published on PubMed (van Zuuren et al., 2023) evaluated treatments for female pattern hair loss and found limited but emerging evidence supporting 5-ARI use in postmenopausal women. Dutasteride is absolutely contraindicated in women who are pregnant or may become pregnant because of teratogenic effects on male fetuses (Category X under the legacy FDA pregnancy classification). The FDA label explicitly prohibits handling of crushed or broken capsules by pregnant women.

Missouri clinicians prescribing dutasteride off-label to postmenopausal women typically document informed consent, confirm post-menopausal status or effective contraception, and note the off-label rationale in the chart. Telehealth platforms vary in whether they prescribe dutasteride to women; patients should ask directly before booking a visit.

Comparing Dutasteride and Finasteride for Missouri Patients

Both drugs are available in Missouri, both have generic versions priced competitively, and both are prescribed via the same telehealth and retail pathways. The choice between them depends on indication, desired DHT suppression depth, side effect profile preference, and cost.

Dutasteride 0.5 mg suppresses DHT by 90 to 95 percent. Finasteride 5 mg (for BPH) or 1 mg (for hair loss) suppresses DHT by approximately 70 percent. A pharmacological comparison published on PubMed (Clark et al., 2004) documented the differential isoenzyme inhibition profile and concluded that the type 1 isoenzyme present in sebaceous glands and scalp follicles may contribute to hair-loss pathology, which is the mechanistic rationale for preferring dutasteride over finasteride in hair restoration.

Generic finasteride 1 mg runs approximately $10 to $20 per month cash pay at Missouri pharmacies, making it about half the out-of-pocket cost of generic dutasteride for patients without insurance coverage of either drug. Finasteride also has a longer track record for hair loss, being FDA-approved for that indication (Propecia) since 1997. The FDA approval history for finasteride is searchable on the FDA Orange Book.

Patients who do not respond adequately to finasteride after six months of consistent use are often switched to dutasteride, given the greater DHT suppression. Missouri telehealth providers routinely manage both medications and can switch prescriptions at follow-up visits.

Step-by-Step: Getting Dutasteride in Missouri Today

1. Choose a prescribing pathway. Book a telehealth visit with a Missouri-licensed provider or schedule an appointment with a Missouri urologist or dermatologist.
2. Prepare your intake information. Have a recent PSA result (within six months) if you are male and over 40, a list of current medications (particularly CYP3A4 inhibitors such as ketoconazole or ritonavir, which can raise dutasteride plasma levels), and your insurance card.
3. Complete the clinical evaluation. The provider reviews your symptom score (AUA Symptom Score for BPH, or a standardized hair-loss assessment for androgenetic alopecia), confirms the diagnosis, and discusses risks.
4. Receive your e-prescription. The prescriber transmits a dutasteride 0.5 mg e-prescription to your chosen Missouri pharmacy. For BPH, a 90-day supply is standard. For hair loss, a 30-day supply is often issued at initiation.
5. Fill at your preferred pharmacy. Retail, mail-order, or 503A compounding pharmacy, depending on formulation and insurance.
6. Schedule follow-up. PSA should be rechecked at six months to establish the new suppressed baseline. The AUA guideline recommends monitoring PSA at six and twelve months after starting a 5-ARI, then annually.

At the six-month mark, a PSA result that has not fallen by at least 50 percent from baseline may suggest nonadherence or, less commonly, the emergence of prostate pathology requiring further evaluation, per the AUA's 2023 BPH guideline recommendation.